Lighthouse Financial Services Inc. ADV Invests $1.02 Million in Merck & Co., Inc. $MRK

Key Points

• Lighthouse Financial Services Inc. ADV initiated a new position in Merck during the fourth quarter, buying 9,728 shares worth about $1.02 million.
• Merck’s recent news flow was mostly positive, including progress on a new biocatalytic synthesis method for its investigational oral PCSK9 inhibitor and a five-year deal making it the sole testing provider for Genetix Biotherapeutics’ FDA-approved gene therapies.
• Despite favorable analyst sentiment overall, Merck faces some headwinds, including Gardasil-related litigation risk and notable insider share sales by top executives.

Lighthouse Financial Services Inc. ADV acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 9,728 shares of the company's stock, valued at approximately $1,024,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. D.A. Davidson & CO. lifted its stake in Merck & Co., Inc. by 4.4% during the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company's stock valued at $60,731,000 after purchasing an additional 24,576 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Merck & Co., Inc. by 48.9% during the 4th quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company's stock worth $10,296,000 after buying an additional 32,114 shares during the period. Coldstream Capital Management Inc. boosted its holdings in shares of Merck & Co., Inc. by 12.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company's stock worth $10,364,000 after buying an additional 13,940 shares during the period. NEOS Investment Management LLC boosted its holdings in Merck & Co., Inc. by 39.9% in the 3rd quarter. NEOS Investment Management LLC now owns 347,684 shares of the company's stock valued at $29,181,000 after purchasing an additional 99,074 shares during the period. Finally, Campbell Capital Management Inc. bought a new stake in Merck & Co., Inc. in the 3rd quarter valued at $1,866,000. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a landmark Science paper on a new large-scale biocatalytic synthesis method for its investigational oral PCSK9 inhibitor, enlicitide decanoate. The work supports manufacturing scalability for a potential future cardiovascular drug and underscores progress in Merck’s pipeline. Article Title
• Positive Sentiment: Merck also became the sole testing provider for Genetix Biotherapeutics’ FDA-approved gene therapies under a five-year agreement, strengthening its BioReliance services business and adding a recurring commercialization-related revenue stream. Article Title
• Neutral Sentiment: Analyst commentary highlighted Merck as a well-prepared dividend stock despite its upcoming patent cliff, suggesting the market is still weighing long-term earnings durability rather than reacting to a single catalyst. Article Title
• Negative Sentiment: Merck is heading toward a July 27 trial over Gardasil safety claims after the vaccine reached an $8.9 billion sales peak. The litigation risk could weigh on sentiment around one of Merck’s key growth franchises, even though the company continues to defend the product’s safety record. Article Title

Insiders Place Their Bets

In other Merck & Co., Inc. news, CMO Chirfi Guindo sold 10,000 shares of the firm's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the transaction, the chief marketing officer directly owned 70,615 shares in the company, valued at approximately $8,361,522.15. This trade represents a 12.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The stock was sold at an average price of $119.15, for a total value of $14,485,422.95. Following the sale, the executive vice president owned 68,916 shares in the company, valued at $8,211,341.40. The trade was a 63.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.17% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Citigroup assumed coverage on shares of Merck & Co., Inc. in a report on Wednesday. They set a "neutral" rating and a $125.00 price target for the company. TD Cowen lifted their price target on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a "hold" rating in a research note on Tuesday, January 20th. Cantor Fitzgerald boosted their price objective on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 4th. Wells Fargo & Company decreased their price objective on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an "overweight" rating on the stock in a report on Friday, May 1st. Finally, Wall Street Zen raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and a consensus price target of $128.18.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $111.26 on Friday. The company has a market capitalization of $274.78 billion, a PE ratio of 31.34, a P/E/G ratio of 2.53 and a beta of 0.18. The company has a 50 day simple moving average of $117.07 and a two-hundred day simple moving average of $108.31. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.30 and a current ratio of 1.30. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Research analysts anticipate that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.